Effects of photobiomodulation therapy on inflammatory mediators in patients with chronic non-specific low back pain: Protocol for a randomized placebo-controlled trial

Shaiane Silva Tomazoni, Leonardo Oliveira Pena Costa, Jon Joensen, Martin Bjørn Stausholm, Ingvill Fjell Naterstad, Ernesto Cesar Pinto Leal-Junior, Jan Magnus Bjordal, Shaiane Silva Tomazoni, Leonardo Oliveira Pena Costa, Jon Joensen, Martin Bjørn Stausholm, Ingvill Fjell Naterstad, Ernesto Cesar Pinto Leal-Junior, Jan Magnus Bjordal

Abstract

Introduction: Low back pain (LBP) is ranked as one of the most prevalent health conditions. It is likely that some inflammatory mediators could be associated with pain and disability in these patients. Photobiomodulation therapy (PBMT) is a non-pharmacological therapy often used in patients with LBP and one of the possible mechanisms of action of therapy is modulate inflammatory mediators. However, to date there are no studies that evaluated the effects of PBMT on the levels of inflammatory mediators in patients with LBP. The aim of this study is to evaluate the acute effects of PBMT on systemic levels of inflammatory mediators and pain intensity in patients with chronic non-specific low back pain.

Methods and analysis: This is a prospectively registered, two-arm randomized placebo-controlled trial with blinded patients, assessors and therapists. Eighteen patients with chronic non-specific LBP will be randomized into 2 groups: placebo or active PBMT. The treatment will be provided in a single session. The primary outcome will be levels of prostaglandin E2 (PGE2). The secondary outcomes will be levels of necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and pain intensity. Biochemical and clinical outcomes will be measured at baseline and 15 minutes after the single treatment session.

Discussion: Despite PBMT be used in musculoskeletal disorders such as LBP, to the best of our knowledge this is the first study that will investigate a possible biological mechanism behind the positive clinical effects of PBMT on non-specific chronic low back pain.

Ethics and dissemination: The study was approved by the Regional Research Ethics Committee. The results will be disseminated through publication in peer-reviewed international journal and conferences.

Trial registration number: NCT03859505.

Conflict of interest statement

Professor Ernesto Cesar Pinto Leal-Junior receives research support from Multi Radiance Medical (Solon, OH), a laser device manufacturer. Multi Radiance Medical had no role in the planning of this study. The remaining authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1
CONSORT flowchart.

References

    1. Hartvigsen J, Hancock MJ, Kongsted A, et al. Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet 2018;391:2356–67.
    1. Tulder MV. Chapter 1. European guidelines. Eur Spine J 2006;15:134–5.
    1. De Queiroz BZ, Pereira DS, Lopes RA, et al. Association Between the Plasma Levels of Mediators of Inflammation With Pain and Disability in the Elderly With Acute Low Back Pain: Data From the Back Complaints in the Elders (BACE)-Brazil Study. Spine (Phila Pa 1976) 2016;41:197–203.
    1. Cui JG, Holmin S, Mathiesen T, et al. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 2000;88:239–48.
    1. Queiroz BZ, Pereira DS, Rosa NM, et al. Functional performance and plasma cytokine levels in elderly women with and without low back pain. J Back Musculoskelet Rehabil 2015;28:343–9.
    1. Wang H, Schiltenwolf M, Buchner M. The role of TNF-Alpha in patients with chronic low back pain-a prospective comparative longitudinal study. Clin J Pain 2008;24:273–8.
    1. Kraychete DC, Sakata RK, Issy AM, et al. Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study. Sao Paulo Med J 2010;128:259–62.
    1. Hasselhorn HM, Theorell T, Vingård E. Musculoskeletal Intervention Center (MUSIC)-Norrtälje Study Group. Endocrine and immunologic parameters indicative of 6-month prognosis after the onset of low back pain or neck/shoulder pain. Spine (Phila Pa 1976) 2001;26:E24–9.
    1. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low back pain: a systematic review for an american college of physicians clinical practice guideline. Ann Intern Med 2017;166:493–505.
    1. Leal-Junior ECP, Lopes-Martins RÁB, Bjordal JM. Clinical and scientific recommendations for the use of photobiomodulation therapy in exercise performance enhancement and post-exercise recovery: current evidence and future directions. Braz J Phys Ther 2019;23:71–5.
    1. Soriano F, Rios R. Gallium arsenide laser treatment of chronic low back pain: a prospective, randomized and double blind study. Laser Ther 1998;10:175–80.
    1. Tantawy SA, Abdelbasset WK, Kamel DM, et al. Laser photobiomodulation is more effective than ultrasound therapy in patients with chronic nonspecific low back pain: a comparative study. Lasers Med Sci 2018;[Epub ahead of print].
    1. De Almeida P, Lopes-Martins RÁ, Tomazoni SS, et al. Low-level laser therapy and sodium diclofenac in acute inflammatory response induced by skeletal muscle trauma: effects in muscle morphology and mRNA gene expression of inflammatory markers. Photochem Photobiol 2013;89:501–7.
    1. De Almeida P, Tomazoni SS, Frigo L, et al. What is the best treatment to decrease pro-inflammatory cytokine release in acute skeletal muscle injury induced by trauma in rats: low-level laser therapy, diclofenac, or cryotherapy? Lasers Med Sci 2014;29:653–8.
    1. Tomazoni SS, Leal-Junior EC, Pallotta RC, et al. Effects of photobiomodulation therapy, pharmacological therapy, and physical exercise as single and/or combined treatment on the inflammatory response induced by experimental osteoarthritis. Lasers Med Sci 2017;32:101–8.
    1. Tomazoni SS, Frigo L, Dos Reis Ferreira TC, et al. Effects of photobiomodulation therapy and topical non-steroidal anti-inflammatory drug on skeletal muscle injury induced by contusion in rats-part 2: biochemical aspects. Lasers Med Sci 2017;32:1879–87.
    1. Aver Vanin A, De Marchi T, Tomazoni SS, et al. Pre-exercise infrared low-level laser therapy (810 nm) in skeletal muscle performance and postexercise recovery in humans, what is the optimal dose? A randomized, double-blind, placebo-controlled clinical trial. Photomed Laser Surg 2016;34:473–82.
    1. Bjordal JM, Lopes-Martins RAB, Iversen VV. A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2. Br J Sports Med 2006;40:76–80.
    1. Chow RT, Johnson MI, Lopes-Martins RA, et al. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet 2009;374:1897–908.
    1. Tomazoni SS, Frigo L, Dos Reis Ferreira TC, et al. Effects of photobiomodulation therapy and topical non-steroidal anti-inflammatory drug on skeletal muscle injury induced by contusion in rats-part 1: morphological and functional aspects. Lasers Med Sci 2017;32:2111–20.
    1. Tomazoni SS, Leal-Junior EC, Frigo L, et al. Isolated and combined effects of photobiomodulation therapy, topical nonsteroidal anti-inflammatory drugs, and physical activity in the treatment of osteoarthritis induced by papain. J Biomed Opt 2016;21:108001.
    1. Grandinétti Vdos S, Miranda EF, Johnson DS, et al. The thermal impact of phototherapy with concurrent super-pulsed lasers and red and infrared LEDs on human skin. Lasers Med Sci 2015;30:1575–81.
    1. Airaksinen O, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006;15:s192–300.
    1. Costa LO, Maher CG, Latimer J, et al. Clinimetric testing of three self-report outcome measures for low back pain patients in Brazil: which one is the best? Spine (Phila Pa 1976) 2008;33:2459–63.
    1. Magee DJ. Orthopedic physical assessment. 62008;Alberta, Canada: Elsevier, 569–618.
    1. Delitto A, George SZ, Van Dillen L, et al. Low Back Pain. Clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association. J Orthop Sports Phys Ther 2012;42:A1–57.
    1. Tomazoni SS, Costa LDCM, Guimarães LS, et al. Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomised placebo-controlled trial. BMJ Open 2017;7:e017202.
    1. Elkins MR, Moseley AM. Intention-to-treat analysis. J Physiother 2015;61:165–7.
    1. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet 2017;389:736–47.
    1. Hicks GE, Fritz JM, Delitto A, et al. Preliminary development of a clinical prediction rule for determining which patients with low back pain will respond to a stabilization exercise program. Arch Phys Med Rehabil 2005;86:1753–62.
    1. Childs JD, Fritz JM, Flynn TW, et al. A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: a validation study. Ann Intern Med 2004;141:920–8.
    1. Tullberg M, Alstergren PJ, Ernberg MM. Effects of low-power laser exposure on masseter muscle pain and microcirculation. Pain 2003;105:89–96.
    1. Albuquerque-Pontes GM, Vieira RP, Tomazoni SS, et al. Effect of pre-irradiation with different doses, wavelengths, and application intervals of low-level laser therapy on cytochrome c oxidase activity in intact skeletal muscle of rats. Lasers Med Sci 2015;30:59–66.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir